Literature DB >> 15734718

Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors?

Javier A Menendez1, Luciano Vellon, Ruth Lupu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15734718     DOI： 10.1177/153537020523000301

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN： 1535-3699


× No keyword cloud information.
  4 in total

Review 1.  Orlistat-associated adverse effects and drug interactions: a critical review.

Authors:  Theodosios D Filippatos; Christos S Derdemezis; Irene F Gazi; Eleni S Nakou; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

2.  Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions.

Authors:  Amira Saleh; Hassan M ElFayoumi; Mahmoud Youns; Waleed Barakat
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-11-21       Impact factor: 3.000

3.  Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo.

Authors:  Shawn Dowling; James Cox; Richard J Cenedella
Journal:  Lipids       Date:  2009-04-21       Impact factor: 1.880

4.  Fatty acid synthase inhibitors induce apoptosis in non-tumorigenic melan-a cells associated with inhibition of mitochondrial respiration.

Authors:  Franco A Rossato; Karina G Zecchin; Paolo G La Guardia; Rose M Ortega; Luciane C Alberici; Rute A P Costa; Rodrigo R Catharino; Edgard Graner; Roger F Castilho; Aníbal E Vercesi
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.